Published in Semin Nucl Med on May 01, 2014
Human Anti-Oxidation Protein A1M-A Potential Kidney Protection Agent in Peptide Receptor Radionuclide Therapy. Int J Mol Sci (2015) 0.80
A review of 3D image-based dosimetry, technical considerations and emerging perspectives in (90)Y microsphere therapy. J Diagn Imaging Ther (2015) 0.75
Quantitative accuracy of 177Lu SPECT imaging for molecular radiotherapy. PLoS One (2017) 0.75
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP (2007) 19.27
Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging (1994) 12.69
Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys (1997) 4.73
Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med (1995) 3.50
The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol (1985) 3.17
MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med (2009) 2.92
Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging (2009) 2.48
MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med (1999) 2.41
99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med (2013) 2.37
Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys (2010) 2.32
Relative biological effectiveness (RBE), quality factor (Q), and radiation weighting factor (w(R)). A report of the International Commission on Radiological Protection. Ann ICRP (2003) 2.32
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11
Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT. J Nucl Med (2013) 2.09
Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys (1991) 1.89
Fast implementations of reconstruction-based scatter compensation in fully 3D SPECT image reconstruction. Phys Med Biol (1998) 1.85
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther (2011) 1.84
A Monte Carlo and physical phantom evaluation of quantitative In-111 SPECT. Phys Med Biol (2005) 1.80
Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med (2007) 1.73
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med (2010) 1.61
Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med (2005) 1.55
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med (2005) 1.51
Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment. Eur J Nucl Med Mol Imaging (2008) 1.51
MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med (1999) 1.44
Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med (2010) 1.42
MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med (2012) 1.40
Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med (2012) 1.39
Development and evaluation of an improved quantitative (90)Y bremsstrahlung SPECT method. Med Phys (2012) 1.29
MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy. J Nucl Med (2008) 1.25
124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med (2009) 1.25
The alpha-camera: a quantitative digital autoradiography technique using a charge-coupled device for ex vivo high-resolution bioimaging of alpha-particles. J Nucl Med (2010) 1.13
Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res (2009) 1.11
Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging (2011) 1.10
Experimental investigation of factors affecting the absolute recovery coefficients in iodine-124 PET lesion imaging. Phys Med Biol (2010) 1.09
MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med (2003) 1.09
Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging (2007) 1.07
Comparison of yttrium-90 quantitative imaging by TOF and non-TOF PET in a phantom of liver selective internal radiotherapy. Phys Med Biol (2011) 1.04
A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys (1987) 1.04
Targeting RAF: trials and tribulations. Nat Med (2011) 1.03
Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci (2010) 1.01
Targeted alpha-therapy: past, present, future? Dalton Trans (2007) 1.01
A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy. Phys Med Biol (2012) 1.00
Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images. J Nucl Med (2003) 0.98
A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry. Phys Med Biol (2012) 0.97
A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy. Int J Radiat Oncol Biol Phys (2010) 0.92
RMDP: a dedicated package for 131I SPECT quantification, registration and patient-specific dosimetry. Cancer Biother Radiopharm (2003) 0.91
Clinical feasibility of fast 3-dimensional dosimetry of the liver for treatment planning of hepatocellular carcinoma with 90Y-microspheres. J Nucl Med (2011) 0.91
Development and validation of RAYDOSE: a Geant4-based application for molecular radiotherapy. Phys Med Biol (2013) 0.88
Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther (2013) 0.88
Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma. J Nucl Med (2012) 0.87
MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications. J Nucl Med (2013) 0.86
Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy. Med Phys (2012) 0.86
Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state. Leuk Lymphoma (2011) 0.86
Tumour control probability derived from dose distribution in homogeneous and heterogeneous models: assuming similar pharmacokinetics, (125)Sn-(177)Lu is superior to (90)Y-(177)Lu in peptide receptor radiotherapy. Phys Med Biol (2012) 0.86
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. Cancer Biother Radiopharm (2007) 0.85
OEDIPE: a personalized dosimetric tool associating voxel-based models with MCNPX. Cancer Biother Radiopharm (2005) 0.85
Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. II. Application of the microdosimetric model to experimental results. Radiat Res (2009) 0.84
Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. I. Presentation and validation of a microdosimetric model. Radiat Res (2009) 0.84
Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images. Phys Med Biol (2013) 0.83
Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET. Q J Nucl Med Mol Imaging (2013) 0.83
Fine-resolution voxel S values for constructing absorbed dose distributions at variable voxel size. J Nucl Med (2010) 0.82
Microdosimetry of astatine-211 using histological images: application to bone marrow. Radiat Res (1997) 0.81
Modelling and dosimetry for alpha-particle therapy. Curr Radiopharm (2011) 0.81
A small-scale anatomic model for testicular radiation dosimetry for radionuclides localized in the human testes. J Nucl Med (2011) 0.80
Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods. J Nucl Med (2012) 0.80
Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Q J Nucl Med Mol Imaging (2009) 0.79
3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART) combined with external beam radiation therapy. Eur J Nucl Med Mol Imaging (2012) 0.78
Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma. J Nucl Med (2013) 0.78
A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging (2010) 0.78
A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po. Nucl Med Biol (2012) 0.77
Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail. Eur J Nucl Med Mol Imaging (2012) 0.77